Last reviewed · How we verify
Trauma
At a glance
| Generic name | Trauma |
|---|---|
| Also known as | psilocybin |
| Sponsor | NWTraumatherapies |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Topical Methylene Blue-Photodynamic Therapy (MB-PDT) for Burn Wound Infection (PHASE1, PHASE2)
- The Experiences of Women With Spinal Cord Injury Regarding Fertility, Contraception and Pregnancy
- Project Tendura: The Impact of Blood Flow Restriction Resistance Training (BFR-RT) in Patients With Achilles Tendon Rupture (ATR) Repair (NA)
- The Effects of 5G Radiation on Skin (NA)
- Examining Analgesic Synergy and Efficacy in Trauma Care (PHASE4)
- CE-STAND: Cervical Epidural STimulation After Neurologic Damage (PHASE1, PHASE2)
- Ischemic Preconditioning Reduces the Severity of Acute Kidney Injury After Partial Nephrectomy (NA)
- Injury Risk Factors in Volleyball Players
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Trauma CI brief — competitive landscape report
- Trauma updates RSS · CI watch RSS
- NWTraumatherapies portfolio CI